Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 80

Every year, more than 5 million people in the USA are diagnosed with heart valve disease, but this condition has no effective long-term treatment. When a person’s heart valve is severely damaged by a birth defect, lifestyle, or aging, blood flow is disrupted. If left untreated, there can be fatal complications.

Valve replacement and repair are the only methods of managing severe valvular heart disease, but both often require repeated surgeries that are expensive, disruptive, and life-threatening. Most replacement valves are made of animal tissue and last up to 10 or 15 years before they must be replaced. For pediatric patients, solutions are extremely limited and can require multiple reinterventions.

Now, Georgia Tech researchers have created a 3D-printed heart valve made of bioresorbable materials and designed to fit an individual patient’s unique anatomy. Once implanted, the valves will be absorbed by the body and replaced by new tissue that will perform the function that the device once served.

Georgia Tech researchers have developed a groundbreaking 3D-printed, bioresorbable heart valve that promotes tissue regeneration, potentially eliminating the need for repeated surgeries and offering a transformative solution for both adult and pediatric heart patients.

Read more | >

A recent study in an animal model provides direct evidence for the role of the vagus nerve in gut microbiome-brain communication, addressing a critical gap in the field.

The research—led by Kelly G. Jameson, as a Ph.D. student in the Hsiao Lab at UCLA—demonstrates a clear causal relationship between and vagal nerve activity. The work is published in the journal iScience.

While the has long been thought to facilitate communication between the gut microbiome—the community of microorganisms living in the intestines—and the brain, direct evidence for this process has been limited. Researchers led by Jameson observed that mice raised without any gut bacteria, known as , exhibited significantly lower activity in their vagus nerve compared to mice with a normal gut microbiome. Notably, when these germ-free mice were introduced to gut bacteria from normal mice, their vagal nerve activity increased to normal levels.

Read more | >

A team of scientists has unlocked a new frontier in quantum imaging, using a nanoscale.

The term “nanoscale” refers to dimensions that are measured in nanometers (nm), with one nanometer equaling one-billionth of a meter. This scale encompasses sizes from approximately 1 to 100 nanometers, where unique physical, chemical, and biological properties emerge that are not present in bulk materials. At the nanoscale, materials exhibit phenomena such as quantum effects and increased surface area to volume ratios, which can significantly alter their optical, electrical, and magnetic behaviors. These characteristics make nanoscale materials highly valuable for a wide range of applications, including electronics, medicine, and materials science.

Read more | >

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

Continue reading “Visceral Fat Removal Extends Lifespan: Which Factors May Reduce Visceral Fat?” | >

Insulin is a key hormone that regulates metabolism in many living organisms. When food is abundant, insulin.

Insulin is a hormone produced by the pancreas, crucial for regulating blood glucose levels. It helps cells in the body absorb glucose from the bloodstream and convert it into energy or store it for future use. Insulin production and action are essential for maintaining stable blood sugar levels. In people with diabetes, the body either does not produce enough insulin (Type 1 diabetes) or cannot effectively use the insulin it does produce (Type 2 diabetes), leading to elevated levels of glucose in the blood. This can cause various health complications over time, including heart disease, kidney damage, and nerve dysfunction. Insulin therapy, where insulin is administered through injections or an insulin pump, is a common treatment for managing diabetes, particularly Type 1. The discovery of insulin in 1921 by Frederick Banting and Charles Best was a landmark in medical science, transforming diabetes from a fatal disease to a manageable condition.

Read more | >

Using the latest brain preservation techniques, could we ever abolish death? And if so, should we?

Watch the Q&A here (exclusively for our Science Supporters): https://youtu.be/iSIIDJS2a2U
Buy Ariel’s book here: https://geni.us/xvi1Ivf.

This lecture was recorded at the Ri on 2 December 2024.

Just as surgeons once believed pain was good for their patients, some argue today that death brings meaning to life. But given humans rarely live beyond a century – even while certain whales can thrive for over two hundred years – it’s hard not to see our biological limits as profoundly unfair.

Yet, with ever-advancing science, will the ends of our lives always loom so close? For from ventilators to brain implants, modern medicine has been blurring what it means to die. In a lucid synthesis of current neuroscientific thinking, Ariel Zeleznikow-Johnston explains that death is no longer the loss of heartbeat or breath, but of personal identity – that the core of our identities is our minds, and that our minds are encoded in the structure of our brains. On this basis, he explores how recently invented brain preservation techniques may offer us all the chance of preserving our minds to enable our future revival, alongside the ethical implications this technology could create.

Join this channel to get access to perks:

Continue reading “Could science abolish death? — with Ariel Zeleznikow-Johnston” | >

While the trial is limited to members of families with genetic mutations that all but guarantee they will develop Alzheimer’s at a young age, typically in their 30s, 40s or 50s, the researchers expect that the study’s results will inform prevention and treatment efforts for all forms of Alzheimer’s disease.

Called the Primary Prevention Trial, the new study investigates whether remternetug — an investigational antibody being developed by Eli Lilly and Company — can remove plaques of a key Alzheimer’s protein called amyloid beta from the brain or block them from accumulating in the first place. Both genetic and nongenetic forms of Alzheimer’s disease start with amyloid slowly collecting in the brain two decades before memory and thinking problems arise. By clearing out low levels of amyloid beta plaques or preventing them from accumulating during the early, asymptomatic phase of the disease, or both, the researchers hope to interrupt the disease process at the earliest stage and spare people from ever developing symptoms.

“We have seen tremendous progress in the treatment of Alzheimer disease in the past few years,” said Eric McDade, DO, a professor of neurology and the trial’s principal investigator. “Two amyloid-targeting drugs were shown to slow symptoms of the disease and have now been approved by the Food and Drug Administration (FDA) as treatments for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. This provides strong support for our hypothesis that intervening when amyloid beta plaques are at the very earliest stage, long before symptoms arise, could prevent symptoms from emerging in the first place.”

The trial is part of the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (Knight Family DIAN-TU), a clinical trials platform designed to find medicines to prevent or treat Alzheimer’s disease. It is closely associated with DIAN, a National Institutes of Health (NIH)-funded international research network led by WashU Medicine that involves research institutes in North America, Australia, Europe, Asia and South America. DIAN follows families with mutations in any of three genes that cause Alzheimer’s at a young age. A child born into such a family has a 50% chance of inheriting such a mutation, and those who do so typically develop signs of dementia near the same age his or her parent did. All the participants in the Primary Prevention Trial come from such families.

“My grandfather passed away from Alzheimer’s, and so did his mother and all but one of his brothers,” said Hannah Richardson, 24, a participant in the Primary Prevention Trial. “My mom and my uncle have been participating in DIAN trials since I was about 10 years old. My mom was always very open about her diagnosis and how it spurred her advocacy for Alzheimer’s research, and I’ve always known I wanted to follow in her footsteps. I am happy to be involved in the Primary Prevention Trial and be involved in research because I know how important it is.”

Continue reading “Primary Prevention Trial” | >

This review discusses the links between the autophagy pathway, aging, and age-associated neurodegeneration in Alzheimer’s, Parkinson’s, motor neuron, and Huntington’s diseases. The authors highlight the functions of autophagy in neurons and glia and how aging and neurodegenerative diseases affect autophagy.

Read more | >

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and University of California San Diego Health. Clots are the second-leading cause of death among cancer patients with advanced disease or aggressive tumors.

While blood clots usually form to stop a wound from bleeding, cancer patients can form clots without injury, plugging up vessels and cutting off circulation to organs. The study, published in Cell, shows that tumors drive clot formation (thrombosis) by releasing chemokines, secreted proteins which then circulate to the lung. Once there, the chemokines prompt immune cells called macrophages to release small vesicles that attach to cell fragments (platelets), forming life-threatening clots.

The findings may lead to to determine blood clotting risk and safer therapies that target the root of the problem to prevent blood clots.

Read more | >

Medical breakthroughs could mean that more of us will live to be 100 or even more, according to longevity medicine expert Dr. Edouard Debonneuil co-founder of the London-based Longevity Clinic who says that modern technology, new medicine, additional medical breakthroughs, and healthy living could help more of us reach that mammoth milestone.

“If the current trend continues, we could see individuals living to 140 or 150 in good health. While that might sound sensational, it’s grounded in science and the longevity field is booming because of these breakthroughs,” said Dr. Debonneuil after a first-of-its-kind study, Rejuvenation Olympics, which produced promising anti-aging results.

“One of the guys taking part is in his 60’s but biologically he resembles someone in their later 30’s. Some participants halved their biological age within two to three years and have reduced their ageing rate by 40 percent. This is a significant leap in human history, we now have the tools to age slowly,” continued Debonneuil.

Read more | >